Bioprosthetic valve monitoring in patients with carcinoid heart disease.
carcinoid heart disease
cardio-oncology
peptide receptor radionuclide therapy (PRRT)
pulmonary valve
pulmonary valve (stenosis) (insufficiency)
telotristat ethyl
tricuspid valve (TV)
tricuspid valve repair
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
10
2022
accepted:
22
12
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Carcinoid heart disease (CnHD) is a frequent cause of morbidity and mortality in patients with neuroendocrine tumors and carcinoid syndrome. Although valve replacement surgery appears to decrease all-cause mortality in patients with advanced CnHD, few studies have investigated the outcomes of patients after valve replacement. We conducted a multi-institution retrospective registry of patients who received both tricuspid and pulmonic bioprosthetic valve (TV/PV) replacements for advanced CnHD from November 2005 to March 2021. Patients were followed post-operatively with echocardiographic studies every 3 months. Carcinoid valvular heart disease scores were used to monitor valve degeneration. Neuroendocrine tumor treatment, their administration times, and associations with echocardiographic findings were recorded. Of 87 patients with CnHD, 22 patients underwent simultaneous surgical TV and PV replacement. In 6 patients (27.3%), increased PV V Bioprosthetic valve degeneration is common in CnHD. Monitoring with echocardiographic studies every 3 months, focusing on PV velocities, could identify patients with occult disease that very likely promotes valve degeneration. Novel neuroendocrine tumor therapies may have a beneficial impact on valve degeneration.
Sections du résumé
Background
UNASSIGNED
Carcinoid heart disease (CnHD) is a frequent cause of morbidity and mortality in patients with neuroendocrine tumors and carcinoid syndrome. Although valve replacement surgery appears to decrease all-cause mortality in patients with advanced CnHD, few studies have investigated the outcomes of patients after valve replacement.
Methods
UNASSIGNED
We conducted a multi-institution retrospective registry of patients who received both tricuspid and pulmonic bioprosthetic valve (TV/PV) replacements for advanced CnHD from November 2005 to March 2021. Patients were followed post-operatively with echocardiographic studies every 3 months. Carcinoid valvular heart disease scores were used to monitor valve degeneration. Neuroendocrine tumor treatment, their administration times, and associations with echocardiographic findings were recorded.
Results
UNASSIGNED
Of 87 patients with CnHD, 22 patients underwent simultaneous surgical TV and PV replacement. In 6 patients (27.3%), increased PV V
Conclusion
UNASSIGNED
Bioprosthetic valve degeneration is common in CnHD. Monitoring with echocardiographic studies every 3 months, focusing on PV velocities, could identify patients with occult disease that very likely promotes valve degeneration. Novel neuroendocrine tumor therapies may have a beneficial impact on valve degeneration.
Identifiants
pubmed: 36712267
doi: 10.3389/fcvm.2022.1072890
pmc: PMC9878394
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1072890Informations de copyright
Copyright © 2023 Honan, Hassan, Deswal, Herrmann, Song, Monlezun, Halperin, Mahvash, Dasari, Koutroumpakis, Akay, Balanescu, de Armas, Patel, Nathan, Kar, Marmagkiolis, Lopez-Mattei, Patel, Gregoric, Yao and Iliescu.
Déclaration de conflit d'intérêts
SH consulting for TerSera and research funding from TerSera. DH consulting for TerSera, ITM, AAA/Novartis, Ipsen, Camurus, Amryt, Crinetics, and Alphamedix and research funding from ITM, AAA/Novartis, Tarveda, Thermo Fisher Scientific, and Genentech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Epidemiology. 2020 Jul;31(4):517-522
pubmed: 32282405
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Curr Opin Endocrinol Diabetes Obes. 2018 Feb;25(1):22-35
pubmed: 29120923
Cancer. 1997 Feb 15;79(4):813-29
pubmed: 9024720
Tex Heart Inst J. 2019 Feb 1;46(1):21-27
pubmed: 30833833
Neth Heart J. 2017 Sep;25(9):471-478
pubmed: 28631210
Heart. 2004 Oct;90(10):1224-8
pubmed: 15367531
Int J Cardiol. 2014 Apr 15;173(1):29-32
pubmed: 24636550
J Am Coll Cardiol. 1998 Oct;32(4):1017-22
pubmed: 9768727
N Engl J Med. 2003 Mar 13;348(11):1005-15
pubmed: 12637610
Ann Thorac Surg. 2009 Jan;87(1):321
pubmed: 19101329
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
N Engl J Med. 1986 Sep 11;315(11):663-6
pubmed: 2427948
J Am Coll Cardiol. 2017 Mar 14;69(10):1288-1304
pubmed: 28279296
Lancet Oncol. 2017 Apr;18(4):525-534
pubmed: 28238592
J Am Soc Echocardiogr. 2009 Jan;22(1):1-23; quiz 101-2
pubmed: 19130998
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Lancet Oncol. 2021 Dec;22(12):1752-1763
pubmed: 34793718
Neuroendocrinology. 2015;101(4):263-73
pubmed: 25871411
Can Assoc Radiol J. 2014 Aug;65(3):214-7
pubmed: 24325922
Cardiology. 2021;146(1):65-73
pubmed: 33070143
Am J Cardiol. 2011 Apr 15;107(8):1221-6
pubmed: 21296329
Ann Thorac Surg. 2016 Dec;102(6):1996-2002
pubmed: 27457832
J Thorac Cardiovasc Surg. 2010 Jun;139(6):1416-9
pubmed: 20363479
Blood Coagul Fibrinolysis. 2018 Jan;29(1):126-128
pubmed: 29016369
Cancer. 2015 Feb 15;121(4):589-97
pubmed: 25312765
Circulation. 2005 Nov 22;112(21):3320-7
pubmed: 16286584
J Clin Oncol. 2017 Jan;35(1):14-23
pubmed: 27918724
J Am Coll Cardiol. 2015 Nov 17;66(20):2189-2196
pubmed: 26564596
J Am Coll Cardiol. 1995 Feb;25(2):410-6
pubmed: 7829795